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Abstract
The present study aimed to demonstrate the use of matrix metalloproteinases (MMP-2, 
MMP-3 and MMP-9) as possible additional biochemical predictors of in-stent restenosis 
(ISR) and determined their reference intervals in adults with respect to gender and age. 
We included 111 consecutive patients treated at the cathlab of the University Hospital 
Ostrava, Czech Republic, with ISR within 12 months after implantation of a bare-metal 
stent. The control group consisted of 111 matched patients with identical main demo-
graphic and clinical risk factors. To set the reference intervals for MMPs, we measured 
the blood concentrations of these analytes in a group of healthy volunteers (N = 180) 
with an average age of 40–50 years. The enzyme concentrations were measured by 
 immunosorbent assay. Statistical analysis was performed using IBM SPSS Statistics ver-
sion 22 and MedCalc Version 14.12. We found that increased levels of MMP-3 and 9 
were associated with a significant increase in ISR risk. The MMP-9 cut-off value for 
ISR risk prediction was determined to be ≥64.8 ng/mL. We suppose that screening of 
these  biochemical parameters might be helpful to a more detailed risk stratification of 
patients after percutaneous coronary interventions, who would be able to benefit from 
implantation of drug-eluting stents.
Keywords: adult, age dependence, enzyme-linked immunosorbent assay, gender  
depen dence, in-stent restenosis, matrix metalloproteinases
1. Introduction
Matrix metalloproteinases (MMPs) are members of a family of zinc-dependent proteolytic 
enzymes. The main function of MMPs is to degrade the various components of the extracellular 
matrix (ECM) and participate as regulators of extracellular tissue signalling networks. MMPs 
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have broad substrate specificity and contribute to the homeostasis of many tissues and partici-
pate in several physiological processes, such as bone remodelling, angiogenesis, immunity and 
wound healing. MMPs are produced by activated inflammatory cells ( neutrophils and mac-
rophages) and wound cells (epithelial cells, fibroblasts and vascular endothelial cells). MMP 
activity is tightly regulated at the level of transcription, pro-peptide activation and inhibition 
by tissue inhibitors of MMPs (TIMPs).
The MMP process represents the procedure of pathologic changes in the tissues in atheroscle-
rosis, arterial remodelling and myocardial repair following infarction [1]. A mechanical dam-
age causes expression of matrix metalloproteinases (MMP), and it is proved that they may 
take part in the pathogenesis of in-stent restenosis (ISR), when undergoing coronary stent 
implantation by percutaneous coronary intervention [2–5].
Effectiveness of percutaneous coronary intervention (PCI) has remarkably become better 
after coronary stent implantation. Thanks to the early obstacles of plane balloon angioplasty 
that could be managed and in case the elastic recoil and constrictive remodelling has been 
applied, it comes to the reduction of the frequency of restenosis after PCI. Although these 
improvements have been implemented, a new complication has occurred in-stent restenosis 
(ISR) caused by neointimal hyperplasia. The clinical probability of occurrence of ISR after 
bare-metal stent implantation is about 20–35% [6, 7]. Additional decline of ISR occurrence to 
5–10% has been caused by the usage of drug-eluting stents [6, 7]. Unfortunately, long-term 
dual antiplatelet therapy needs to be applied and is connected with the threat of late and very 
late stent thrombosis. The known predictors of ISR include patient-, vessel- and procedure-
related agents [6, 7]. Because of not decreasing amount of patients going through PCI, there 
were strives to find other predisposing factors that would lead to more focused treatment.
2. Aims
We focused on matrix metalloproteinases (MMP-2, MMP-3 and MMP-9) as possible  additional 
biochemical predictors of in-stent restenosis (ISR) after coronary artery bare-metal stenting 
and determined their reference intervals in adults with respect to gender and age.
3. Patient group and methods
Note that, 111 patients were recruited from the University Hospital Ostrava, Czech Republic 
affected by ISR within 12 months after implantation of a bare-metal stent. The control group 
(n = 111) with absent ISR 12 months after implantation of a bare-metal stent coincided with 
patients treated at our cathlab with identical main demographic and clinical risk factors (sex, 
age, diabetes mellitus and implanted stent diameter ±0.5 mm).
To set the reference intervals for MMP-2, MMP-3 and MMP-9, we measured the blood con-
centrations of these analytes in a group of 180 healthy adult volunteers attending the Blood 
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Centre of the University Hospital Ostrava. We measured MMP concentrations in heparin 
plasma. Plasma samples from each patient and healthy volunteers were stored at −80°C for 
2–3 months after centrifugation at 2500 × g at 4°C for 6 min and in 2 aliquots of 2 mL. The 
measurement of enzyme concentrations was performed by immunosorbent assay (ELISA) 
(BioVendor-Laboratorni Medicina a.s., Brno, Czech Republic).
Selective coronarography was determined in a Siemens Axiom device (Forchheim, Germany) 
in a common way from the radial approach with 5 F diagnostic catheters and the contrast 
medium Iomeron 400. Quantitative coronary angiography was executed, and percent diam-
eter stenosis (%DS) was figured out. ISR was observed as a diameter stenosis ≥50% in the 
stented segment.
Multi-slice CT coronarography was assessed in all patients in the Siemens Somatom Definition 
AS + device (Forchheim, Germany), a single-source CT scanner in a 128-slice configuration. 
The maximum intensity projection (MIP) reconstructions and automatic software vessel anal-
ysis were applied for assessment of the lumen. Homogeneous enhancement (from the visual 
point of view, similar to the CT attenuation in the reference vessels) inside the stent lumen 
was reported to be normal or without any relation to ISR [8].
Statistical analysis was performed using IBM SPSS Statistics version 22 (SPSS Inc., Chicago, 
IL, USA). Measured biochemical parameters were categorized according to reference val-
ues, which were calculated using MedCalc Version 14.12 (origin) [9, 10]. Parametric and 
non-parametric statistical methods were applied, as appropriate, using NCSS 2007 (origin) 
for calculations and R software for graphical displays. Potential outliers were evaluated by 
Cook’s distance and partitioning of the data according to Harris and Boyd [11]. There were 
linkages between measurands, which were assessed using Spearman’s rank correlation (r
s
) 
or Pearson’s product-moment correlation coefficients (r
p
), respectively. What is more, cor-
relation testing, the age dependence of MMP-2 and MMP-3 was examined using piecewise 
polynomial models (multiphase models) [12].
Continuous variables with non-normal distribution are presented as the median and range 
(minimum−maximum) and were compared using the non-parametric Mann-Whitney U 
test. Categorical variables were compared by the chi-square test. The difference between 
measured biochemical parameters of the study and control groups was analysed by the 
chi-square test. The assessment of potential consequences of other features on the asso-
ciation observed between the levels of individual markers and ISR was applied multiple 
logistic regression. A forward stepwise method was used to establish the most notable risk 
values for ISR. Diabetes mellitus and other possible confounding variables have been taken 
into consideration. The stating of the optimal cut-off values of biochemical criteria was 
applied the receiver operating characteristic (ROC) analysis in order to prognosticate in-
stent restenosis.
The studied protocol complied with the declaration of Helsinki and was approved by the 
Ethics Committee of the University Hospital Ostrava, Czech Republic. Written informed con-
sent was obtained from each participant.




There have not been found any remarkable differences in the patients with ISR and the control 
group, as far as the main demographic factors (age, gender and body mass index) or  clinical 
risk factors (diabetes mellitus) concerned. Same ranges of coronary disease ( multi-vessel dis-
ease, acute coronary syndromes) and similar lesion characteristics (complex lesion B2/C and 
length and diameter (±0.5 mm) of implanted stents) have been proved in the groups. What 
is more, in both groups, mostly similar biochemical criteria have been found (creatinine, glu-
cose, triglycerides, High-density lipoprotein (HDL) and hsCRP). Nevertheless, the ISR group 
showed particularly lower total cholesterol (p = 0.016) and Low-density lipoprotein (LDL) 
(p = 0.001), and notably higher NT-pro-BNP (p = 0.010), in comparison to the treatment group. 
Table 1 shows the summary of plasma levels of matrix metalloproteinases in all groups [13].
To set the reference intervals for MMP-2, MMP-3 and MMP-9, we measured the blood concen-
tration in a group of healthy volunteers with an average age of 40–50 years. Plasma MMP-2 
levels in these population showed statistically significant age dependence (r
p
 = 0.171; p = 0.02; 
r
s
 = 0.161; p = 0.034). Therefore, we divided the tested file into two groups: ≤49 and >50 years. The 
medians of these age groups were significantly different from each other (p = 0.001; z = 3.15). 
MMP-3 plasma concentrations were found to be significantly correlated with age (r
p
 = 0.355; 
p = 0.00007; r
s
 = 0,308; p = 0.0006) as well as with gender (p ≤ 0.001; z > 3.0). Because of this, there 
were created two groups of the probands, according to the age ≤47 and >47 years. The depen-
dence of the measured values on gender showed to be crucial. Since, only a small amount of 
men in the group of ≤47 years took part in the survey, the reference range has not been taken 
into account for this group. No statistically significant changes could be observed in plasma 
MMP-9 levels in relation to age, but there was found a link with gender (p = 0.014; z = 2.39). 
Because of the fact that the z-value was lower than 3 and the data performed a non-Gaussian 
distribution, the distribution in separate age-dependence subgroups was figured out. The ref-
erence ranges are depictured in Table 2. Table 3 presents an outline of the results [14].
Furthermore, we compared the levels of plasma of matrix metalloproteinases in ISR patients 
with the normal reference values of these markers in the healthy population.
The correlation between MMP-3, MMP-9 and the incidence of ISR with respect to diabetes 
mellitus was studied using a logistic regression analysis. It was shown that MMP-3 (OR: 1.013, 
95% CI: 1.004–1.023, p = 0.005) and MMP-9 (OR: 1.014, 95% CI: 1.008–1.020, p < 0.0001) are 
significantly associated with the occurrence of ISR (Table 4).
Methods In-stent restenosis Controls
MMP-2 (ng/mL) 173.76 (122.18–248.40) 163.58 (113.57–247.85)
MMP-3 (ng/mL) 43.37 (26.66–72.74) 31.48 (23.14–53.16)
MMP-9 (ng/mL) 88.40 (53.80–131.7) 44.90 (25.56–79.90)
Note: Data are given as median (lower and higher quartiles).
Table 1. Plasma levels of measured parameters of all patients and matched controls [13].
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The result of this study is also the finding that the decreased concentration of MMP-9 below 
the lower limit of the reference interval is associated with a significant reduction in the 
incidence of ISR (OR: 0.265, 95% CI: 0.121–0.582, p = 0.001). On the other hand, the increased 
concentration of MMP-9 above the upper limit of the reference interval is associated with 
an increase in the incidence of ISR (OR: 2.685; 95% CI: 1.344–5.366; p = 0.005). At the same 
time, the increased concentration of MMP-3 above the upper limit of the reference interval 
Analyte N Age (year) Gender 2.5th 90thconfidence 
interval
97.5th 90th confidence 
interval
MMP-2 (ng/mL) 180 35–62 Both 110.0 97.1–124.1 590.9 520.8–670.0
111 35–49 Both 98.3 83.0–115.2 466.9 417.9–519.1
62 50-62 Both 160.8 144.8–179.0 550.2 456.9–666.7
MMP-3 (ng/mL) 120 34–61 Both 12.49 11.20–13.86 39.37 36.19–42.72
38 34–47 Female 11.11 9.24–13.15 29.91 26.49–33.53
14a Male – – – –
22 48–61 Female 12.76 11.11–14.69 31.14 25.41–38.40
46 Male 18.03 15.84–20.38 42.04 38.00–46.33
MMP-9 (ng/mL) 116 16–61 Both 27.63 24.55–30.99 103.06 92.85–114.06
58 20–61 Female 24.83 20.93–29.25 98.82 84.28–115.27
58 19–55 Male 33.37 29.47–37.77 108.67 93.01–126.8
a Reference interval cannot be calculated due to the small number of data.
Table 2. The gender- and age-dependent reference intervals of MMP-2, MMP-3 and MMP-9 (μg/l)—2.5th, 97.5th centile 
values and their 90th confidence intervals according to parametric statistical methods [14].




Table 3. Summary of results as regards age- and gender-dependence of MMP-2, MMP-3 and MMP-9 [14].
Analyte OR 95% CI for OR p
MMP-2 1.001 0.999–1.004 0.326
MMP-3 1.013 1.004–1.023 0.005
MMP-9 1.014 1.008–1.020 <0.0001
Note: OR is associated with a single-unit increase in the value of the parameter.
Table 4. Logistic regression analysis (separately for each parameter with adjustment for diabetes mellitus (DM)) [13].
Matrix Metalloproteinases MMP-3 and MMP-9 as Predictors of In-Stent Restenosis
http://dx.doi.org/10.5772/intechopen.69589
61
is linked with an increased incidence of ISR (OR: 2.502; 95% CI: 1.441–4.344; p = 0.001). In 
this case, a multivariate logistic regression analysis was also used. A step-by-step method 
was used to select the most important categorized parameters that are predictive of ISR, 
with DM modifications and individual categorized parameters. It was found that MMP-9 
is the most important parameter in terms of ISR prediction (OR: 0.322; 95% CI: 0.122–0.854; 
p = 0.023), its decrease below the lower limit of the reference interval is connected with a 
decrease in ISR.
Based on receiver operating characteristic (ROC) analysis, the plasma abundance of MMP-9 may 
be considered the most suitable parameter for use in ISR risk prediction (Table 5 and Figure 1). 
The following cut-off values for prediction of ISR were determined: MMP-9 ≥ 64.8 ng/mL with 





Note: Parameters with AUC > 0.7 or > 0.75 are suitable for the in-stent restenosis prediction.
Table 5. ROC analysis; area under the curve (AUC) of all parameters [13].
Figure 1. ROC curve of MMP-9 with AUC >0.7 is suitable for the ISR prediction [13].
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5. Discussion
MMPs are a growing family of endopeptidases, they currently have at least 24 mem-
bers, although some of them have not been well understood. Most of the MMPs contain a 
 pro-peptide, a catalytic domain, a linker peptide and a hemopexin domain. MMPs are syn-
thesized and secreted as latent pro-enzymes, containing a Zn2+-binding active site and require 
Ca2+ for activation. MMPs are categorized by their structure and substrates into collagenases, 
gelatinases, stromelysins, matrilysins, membrane-type (MT)-MMPs and others. MMP-2 
( gelatinase A) and MMP-9 (gelatinase B) are classified as a gelatinases, which degrade both 
collagens and gelatins [1].
MMP-2 and MMP-9 play an essential role in angiogenesis and arteriogenesis, two processes 
are critical to restoration of tissue perfusion after ischemia. MMP-2 expression is increased in 
tissue ischemia, but the responsible mechanisms remain unknown.
Expression and activity of MMPs are regulated at different levels: gene expression, proen-
zyme activation and enzyme secretion are inhibited specifically by tissue inhibitors of MMPs 
(TIMPs) and non-specifically alpha-2 macroglobulin. There is an increased expression of the 
genes encoding these proteins. Mutations of these genes are likely to affect the degree of 
expression, mRNA stability and the properties of the particular proteins, which may influ-
ence the process etiopathogenesis.
MMP-2 and MMP-9 are the most widely studied MMPs in blood vessel. MMP-3 ( stromelysin-1) 
is included among stromelysins and is digested a wide range of extracellular matrix mole-
cules and participated in proMMPs proteolysis. MMP-3 overexpression significantly reduces 
smooth muscle cells migration and inhibits neointimal formation in arterialized vein grafts. 
Ogata et al. reported that MMP-3 regulates vascular smooth muscle cells migration via 
MMP-9 activation. MMP-3 is already known as an activator of pro-MMP-9. Combination of 
MMP-3 and MMP-9 is required and efficient in neointimal hyperplasia [15–17].
Analyte MMP-9
AUC 0.715





False positivities 34.2% 25.5–43.8%
False negativities 34.2% 25.5–43.8%
Table 6. Cut-off values of MMP-9 for ISR prediction [13].
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Based on several published studies describing the discrepancies in MMP concentrations 
between serum and plasma [18–31], we measured MMP concentrations in heparin plasma. To 
set the reference intervals for MMP-2, MMP-3 and MMP-9, we measured the blood concentra-
tions of these analytes in a group of healthy volunteers with an average age of 40–50 years. We 
found that plasma MMP-2 concentrations depend on the proband age (healthy volunteers). 
Lower MMP-2 concentrations were found in subjects <50 years of age and the concentration 
increased with age. However, no similar data were reported for a group of healthy volunteers.
The concentration of MMP-3 was statistically significant correlated with age and sex as well. 
The lower plasma concentrations of MMP-3 have been demonstrated in probes <47 years. 
MMP-3 concentrations in women were lower in both age groups than that in men.
Normal levels for MMP-3 determined by a one-step sandwich ELISA method with reagents 
provided by Dr Jaspar, Biosource Europe S. A., Belgium were described in 96 healthy controls 
(46 females and 50 males) in the study of Ribbens et al. [32, 33]. Our results showed higher 
plasma MMP-3 concentration in both women and men, as compared to Ribbens et al.’s data. 
The cause of this difference seems to be the use of different reagents.
Plasma MMP-9 concentrations are associated with difference in respect to gender. Our find-
ings indicate lower values in women and higher in men. The publication of Lizasa et al. [34] 
also evaluated a group of healthy volunteers (n = 138). They used the plasma samples without 
any further specification of primary material and one-step sandwich enzyme immunoassay 
kit (Fuji Chemical Industries, Toyama, Japan) for their determination. Their results showed a 
common range of plasma MMP-9 concentration lower than our data and independent of gen-
der or age. They also failed to mention the age variance of their healthy volunteers. It is found 
from other published studies that the measured concentrations of not only MMP-9 but also 
of other MMPs in blood are strongly influenced by the sampling procedure and by the type 
of used anticoagulant agent [18–31]. These reasons may stand for the found differences. Such 
differences in methodology could underlie the observed discrepancy between these studies.
These normal values were used for comparison of patients with in-stent restenosis after PCI 
and matched controls.
Percutaneous coronary intervention (PCI) is a rapid transduction of the coronary artery in 
most cases by means of a balloon catheter. Concomitant implantation of the coronary stent, 
which prevents the re-narrowing of the coronary artery, has reached a significant improve-
ment in PCI. However, a new complication occurs: stent restenosis (ISR), developing from 
neointimal hyperplasia, which the basic element, is the transformation of smooth muscle cells 
from the contractile to the proliferative phenotype. The process of restenosis is initiated by 
endothelial denudation and deep vascular damage that starts adhesion and platelet activa-
tion. Activated platelets exclude growth factors that release smooth muscle cells from growth 
inhibition and induce their proliferation and subsequent migration from the media into the 
intimate. Proliferation of smooth muscle cells continues after the platelet phase. Activated 
smooth muscle cells themselves exclude growth factors that can affect the surrounding cells 
and help to maintain proliferation and migration. The second fundamental element of reste-
nosis is the production and secretion of extracellular matrix by smooth muscle cells that 
migrated to the injured intimal zone. A complete neointimal layer can be observed already 2 
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weeks after implantation of the stent. Maximum restenosis is observed after 3–6 months and 
remains relatively stable after 1 year [6, 7].
To exclude ISR was used Multi-slice coronarography (MS-CT) coronarography due to non-inva-
siveness in the control group. Note that, 64- and more-slice MS-CT have almost 99% sensitivities 
and specificities for the detection of coronary artery stenoses in the native coronary arteries.
Visualization of the lumen inside the metal stents of the coronary artery by MS-CT is more 
demanding than the assessment of the native coronary artery with respect to the material 
used for stent manufacturing [35].
Sun [36] and Kumbhani [37] in their study described the advantages of MS-CT in detecting 
stent coronary restenosis (nearly 1400 and 1500 evaluated stents).
The sensitivity and specificity of MS-CT in detection of ISR were 90 and 91%, with positive 
and negative predictive values of 68 and 98%, respectively [36, 37].
In this study, the results of ISR patients were compared with those of the control group. 
Increased plasma concentrations of MMP-3 and MMP-9 were found to be significantly associ-
ated with a significant increase in ISR risk. The MMP-9 cut-off value for ISR risk prediction 
was determined to be ≥64.8 ng/ml. At the same time, no correlation between the MMP-2 val-
ues and the ISR occurrence has been demonstrated.
6. Conclusions
Age- and gender-specific reference intervals for heparin-plasma MMP-2, MMP-3 and MMP-9 
were established based on a cohort of healthy subjects. Transference studies suggest that 
these intervals established by enzyme-linked immunosorbent assay are not comparable to 
published data mainly because of different type of used anticoagulant agent. In addition to 
this, each laboratory should have these reference intervals checked for its own population 
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines.
At the same time, a statistically significant correlation has been demonstrated between 
increased MMP-3 and MMP-9 concentrations and an increased risk of ISR. For predicting 
the risk of ISR, the concentration of ≥ 64.8 ng/ml MMP-9 was determined. No correlation was 
demonstrated between MMP-2 concentration and ISR occurrence.
We suppose that screening of these biochemical parameters might be helpful to a more 
detailed risk stratification of patients after percutaneous coronary interventions, who would 
be able to benefit from implantation of drug-eluting stents.
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